PMID- 26302654
OWN - NLM
STAT- MEDLINE
DCOM- 20160830
LR  - 20181113
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 99
DP  - 2015 Dec
TI  - Intravenous self-administration of entactogen-class stimulants in male rats.
PG  - 538-45
LID - S0028-3908(15)30075-7 [pii]
LID - 10.1016/j.neuropharm.2015.08.030 [doi]
AB  - The intravenous self-administration (IVSA) of 3,4-methylenedioxymethamphetamine 
      (MDMA) is inconsistent in rats, with up to half of subjects failing to acquire 
      reliable drug intake. It is unknown if this changes under long-access conditions 
      (6 h sessions) under which the IVSA of cocaine and methamphetamine escalates. The 
      entactogen class cathinone stimulants which exhibit MDMA-like monoamine effects 
      in the nucleus accumbens, mephedrone (4-methylmethcathinone) and methylone 
      (3,4-methylenedioxymethcathinone), may support more reliable IVSA but results 
      have been mixed. This study was designed to directly compare the IVSA of these 
      three compounds. Groups of male Wistar rats were trained to self-administer 
      mephedrone, methylone or MDMA (0.5 mg/kg/inf) under a Fixed-Ratio (FR) 1 schedule 
      of reinforcement for 14 sessions. Following the acquisition interval, animals 
      were evaluated in FR (0.0, 0.125, 0.25, 0.5, 1.0, 2.5 mg/kg/inf) and Progressive 
      Ratio (PR; 0.125, 1.0 mg/kg/inf) dose-substitution procedures. Long access 
      conditions escalated MDMA intake over the 6 h session but not in the first 2 h. 
      In short access, drug intake was significantly higher in mephedrone-trained rats 
      compared with either the methylone-trained or MDMA-trained groups during 
      acquisition. Mephedrone resulted in the highest intakes during FR and PR 
      dose-substitution in MDMA- and mephedrone-trained groups. Overall it was found 
      that mephedrone is a more effective reinforcer than methylone or MDMA and 
      represents a higher risk for compulsive use.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Vandewater, Sophia A
AU  - Vandewater SA
AD  - Committee on the Neurobiology of Addictive Disorders, The Scripps Research 
      Institute, La Jolla, CA, USA.
FAU - Creehan, Kevin M
AU  - Creehan KM
AD  - Committee on the Neurobiology of Addictive Disorders, The Scripps Research 
      Institute, La Jolla, CA, USA.
FAU - Taffe, Michael A
AU  - Taffe MA
AD  - Committee on the Neurobiology of Addictive Disorders, The Scripps Research 
      Institute, La Jolla, CA, USA. Electronic address: mtaffe@scripps.edu.
LA  - eng
GR  - R01 DA024105/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150821
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Central Nervous System Stimulants)
RN  - 44RAL3456C (Methamphetamine)
RN  - 8BA8T27317 (mephedrone)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - L4I4B1R01F (methylone)
SB  - IM
MH  - Administration, Intravenous
MH  - Amphetamine-Related Disorders
MH  - Animals
MH  - Catheters, Indwelling
MH  - Central Nervous System Stimulants/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Male
MH  - Methamphetamine/administration & dosage/*analogs & derivatives
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage
MH  - Rats, Wistar
MH  - Self Administration
MH  - Sex Characteristics
PMC - PMC4655153
MID - NIHMS719512
OTO - NOTNLM
OT  - Bath salts
OT  - Drug addiction
OT  - Ecstasy
OT  - Reward
OT  - Substance abuse
EDAT- 2015/08/26 06:00
MHDA- 2016/08/31 06:00
PMCR- 2016/12/01
CRDT- 2015/08/26 06:00
PHST- 2015/03/24 00:00 [received]
PHST- 2015/08/17 00:00 [revised]
PHST- 2015/08/18 00:00 [accepted]
PHST- 2015/08/26 06:00 [entrez]
PHST- 2015/08/26 06:00 [pubmed]
PHST- 2016/08/31 06:00 [medline]
PHST- 2016/12/01 00:00 [pmc-release]
AID - S0028-3908(15)30075-7 [pii]
AID - 10.1016/j.neuropharm.2015.08.030 [doi]
PST - ppublish
SO  - Neuropharmacology. 2015 Dec;99:538-45. doi: 10.1016/j.neuropharm.2015.08.030. 
      Epub 2015 Aug 21.